Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Lung Cancer
Sarcoma
Solid Tumor
Unknown Primary
18 Years and older, Male and Female
209012 (primary)
NCI-2020-11491
Summary
This trial will evaluate the safety and efficacy of first time in human engineered T-cell
therapies, in participants with advanced tumors.
Objectives
New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumor-associated proteins
that have been found in several tumor types. Clinical trials using adoptively transferred
T-cells directed against NY-ESO-1 have shown objective responses. GSK3901961, GSK3845097 and
GSK4427296 are next generation engineered T-cell receptor (TCR) T-cells, co-expressing the
cluster of differentiation 8 (CD8) alpha cell surface receptor, targeting NY-ESO-1,
co-expressing the dominant-negative TGF-beta receptor type II (dnTGF-beta RII) cell surface
receptor, targeting NY-ESO-1, and engineered using the Epigenetically Reprogrammed (Epi-R)
manufacturing process, respectively to potentially improve function. This is a master
protocol evaluating first time in human T-cell therapies. It currently consists of three
independent substudies, investigating GSK3901961, GSK3845097 and GSK4427296 in human
leukocyte antigen (HLA)-A*02 positive participants with NYESO1+ previously treated advanced
(metastatic or unresectable) synovial sarcoma (SS)/myxoid/round cell liposarcoma (MRCLS)
and/or previously treated metastatic non-small cell lung cancer (NSCLC).
Eligibility
- Participant must be >=18 years of age and weighs =40 kg on the day of signing informed consent
- Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles
- Participant's tumor must have tested positive for NY-ESO-1 and/or LAGE-1a expression by a GSK designated laboratory
- Performance status: Eastern Cooperative Oncology Group of 0-1
- Participant must have adequate organ function and blood cell counts 7 days prior to leukapheresis
- Participant must have measurable disease according to RECIST v1.1. Additional criteria for participants with SS/ MRCLS:
- Participant has advanced (metastatic or unresectable) SS or MRCLS confirmed by local histopathology with evidence of disease-specific translocation
- Participant has completed at least one standard of care (SOC) treatment including anthracycline containing regimen unless intolerant to or ineligible to receive the therapy. Participants who are not candidates to receive anthracycline should have received ifosfamide unless also intolerant to or ineligible to receive ifosfamide. Participants who received neoadjuvant/adjuvant anthracycline or ifosfamide based therapy and progressed will be eligible Additional criteria for participants with non-small cell lung cancer (NSCLC):
- Participant has Stage IV NSCLC as confirmed by histology or cytology
- Prior therapies for participants lacking actionable genetic aberrations (i.e., wild type), per National Comprehensive Cancer Network (NCCN) guidelines: participant has been previously treated with or is intolerant to programmed death receptor-1 (PD)-1/Programmed death ligand 1 (PD-L1) checkpoint blockade therapy and has been previously treated with or is intolerant to a platinum-based chemotherapy. Adjuvant therapy will count as a regimen if completed within 6 months before relapse. Or for participants that harbors an actionable genetic aberration (e.g. BRAF, anaplastic lymphoma kinase [ALK]/ c-ros oncogene 1 [ROS1] etc.), per NCCN guidelines: participants has been previously treated with or is intolerant to SOC therapy, including targeted therapy, as recommended by NCCN or equivalent country-level guidelines (European Society for Medical Oncology [ESMO], National Institute for Health & Care Excellence [NICE]) . Or Investigator has decided that additional lines of SOC therapy after the first line are not in the participant's best interest.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.